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Abstract
Background: Guidelines suggest observation stays are appropriate for pulmonary embolism (PE) patients at low-risk
for early mortality. We sought to assess agreement between United States (US) observation management of PE and
claims-based and clinical risk stratification criteria.
Methods: Using US Premier data from 11/2012 to 3/2015, we identified adult observation stay patients with a primary
diagnosis of PE, ≥1 PE diagnostic test claim and evidence of PE treatment. The proportion of patients at high-risk was
assessed using the In-hospital Mortality for PulmonAry embolism using Claims daTa (IMPACT) equation and high-risk
characteristics (age > 80 years, heart failure, chronic lung disease, renal or liver disease, high-risk for bleeding, cancer or
need for thrombolysis/embolectomy).
Results: We identified 1633 PE patients managed through an observation stay. Despite their observation status,
IMPACT classified 46.4% as high-risk for early mortality and 33.3% had ≥1 high-risk characteristic. Co-morbid heart
failure, renal or liver disease, high-risk for major bleeding, cancer and hemodynamic instability were low (each <4.5%),
but 7.8% were >80 years-of-age and 19.4% had chronic lung disease.
Conclusion: Many PE patients selected for management in observation stay units appeared to have clinical
characteristics suggestive of higher-risk for mortality based upon published claims-based and clinical risk
stratification criteria.
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Background
Current guidelines suggest low-risk pulmonary embolism
(PE) patients are candidates for treatment at home or with
an abbreviated hospital stay versus ~5+ days of in-hospital
management [1]. Prior studies suggest up to 50% of PE
patients may be treated in such a fashion [2].
In the United States (US), observation stays are intended
to manage patients for short periods to determine
appropriateness for inpatient admission, with the deter-
mination of admission/discharge occurring within 2-
midnights. Observation stays may serve as an alternative
to inpatient management for low-risk PE patients. Reim-
bursement policy changes have led to an increasing use of
observation stays [3–6]. We assessed agreement between
observation management of PE and claims-based and
clinical risk stratification criteria using administrative
claims data.
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Methods
We performed a retrospective analysis using Premier
claims data from 11/2012 to 3/2015. Premier captures
~20% of all discharges from US acute care hospitals. This
study was performed in accordance with the Declaration
of Helsinki. All data included in the Premier Perspective
Comparative Hospital Database are de-identified and are
in compliance with the Health Insurance Portability and
Accountability Act (HIPAA) of 1996 to preserve partici-
pant anonymity and confidentiality. For this reason, this
study was exempt from institutional review board over-
sight and did not require an approval by an ethics com-
mittee. The data used in this study was under license from
Premier Inc. and provided through the study sponsor,
Janssen Scientific Affairs, LLC.
To be included, adult patients had to have undergone
an observation stay (self-reported by hospitals) with an
International Classification of Diseases, 9th-revision
(ICD-9) diagnosis code for PE (415.1x) in the primary
position, have a claim for ≥1 diagnostic test for PE on
day 0–2 (computed tomography, ventilation-perfusion
scan, pulmonary angiography) and received pharmacologic
(anticoagulation, thrombolysis) and/or non-pharmacologic
(pulmonary embolectomy, filter placement) PE treat-
ment [1].
Patient risk for early post-PE mortality was assessed
using the validated In-hospital Mortality for PulmonAry
embolism using Claims daTa (IMPACT) equation [1/(1 +
exp(−x)); x = −5.833 + (0.026 × age) + (0.402 ×myocardial
infarction) + (0.368 × chronic lung disease) + (0.464 ×
stroke) + (0.638 × prior major bleeding) + (0.298 × atrial
fibrillation) + (1.061 × cognitive impairment) + (0.554 ×
heart failure) + (0.364 × renal failure) + (0.484 × liver
disease) + (0.523 × coagulopathy) + (1.068 × cancer)], with
an estimated in-hospital mortality risk >1.5% deemed
higher-risk [7–9]. We also determined the proportion of
patients with characteristics placing them at higher-risk
for early mortality or other complications included in the
simplified PE severity index (sPESI) or Hestia criteria
(age > 80 years, heart failure, chronic lung disease, renal
impairment, liver disease, high-risk for major bleeding,
cancer or a need for early thrombolysis/embolectomy
[proxy for hemodynamic instability]) when assessable in
the claims database [10, 11].
IMPACT mortality risk and patient characteristics
were summarized using descriptive statistics. Percent-
ages and means ± standard deviations or medians (25%,
75% range) were used to summarize categorical and con-
tinuous data. Statistical analysis was performed in IBM
SPSS v22 (IBM Corp., Armonk, NY, USA).
Results
In total, 47,607 hospital encounters for PE were identi-
fied and 3.4% were coded as observation stays. Using
IMPACT, ~46% of observation stay patients were at
higher-risk for early post-PE mortality (Table 1). Over
one-third of PE patients managed via an observation stay
had ≥1 criteria placing them at high-risk for early mortality.
The proportion of patients with co-morbid heart failure,
renal or liver disease, high-risk for major bleeding, cancer
and requiring thrombolysis/pulmonary embolectomy were
low (<4.5% for each), but 7.8% patients were >80 years-of-
age and 19.4% had chronic lung disease. One patient died
during hospitalization (out-of-hospital mortality is not
available in Premier) and 28% stayed >2-midnights. High-
risk patients by IMPACT or those with ≥1 high-risk criteria
had longer length-of-stay (p ≤ 0.005 for both using a
generalized linear model with a gamma distribution
and log-link).
Discussion
Our study suggest anywhere from one-third to about
half of PE patients managed via an observation stay in
the US would be classified as higher-risk for early post-
PE mortality according to claims-based or clinical risk
stratification criteria [7–11]. Advanced age and chronic
lung disease were the most frequent “high-risk” charac-
teristics identified in observation stay-managed patients.
The substantial proportion of observation stay patients
in our study classified at higher-risk by IMPACT and se-
lect components of the sPESI and the Hestia criteria
highlights the lack of agreement between US observation
management of PE and risk stratification tools. Whether
this observed disagreement suggests inappropriate use of
observation stays is unknown. It does suggest; however,
that risk stratification tools may be used infrequently by
practitioners in routine practice [12–14]. Studies have
reported common clinician barriers to using risk stratifi-
cation tools including difficulties in implementation in
routine practice [12, 13], lack of training in their use,
regulatory constraints and the nature of the physician-
patient relationship [14]. Also of concern, risk stratifica-
tion tools tend to oversimplify risk assessment (accurately
identifying those at very low-risk, but classify a large ma-
jority who inevitably do not experience a complication as
higher-risk) [12]. This overall lack of prognostic accuracy
likely explains some inconsistencies between tool recom-
mendations and clinical gestalt.
Whether clinical gestalt alone is optimal for identifying
PE patients suitable for abbreviated stays is unclear. In a
meta-analysis by Piran et al. [15], the pooled risk of recur-
rent venous thromboembolism in outpatient-treated PE
patients was shown not to differ between clinical gestalt
and risk stratification methods (1.9% vs. 1.4%). Of note,
nearly all studies examined in this meta-analysis were con-
ducted in non-US centers decreasing its generalizability to
US practice. Future studies to determine the prognostic
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accuracy of clinical gestalt in comparison to accepted risk
stratification tools are needed.
Our study has limitations worth noting. First, Premier
does not provide access to clinical data including vital
signs (e.g., blood pressure, heart or respiratory rate, oxy-
gen saturation), out-of-hospital mortality or clot burden.
Thus, we could not apply commonly used clinical cri-
teria, tools such as PESI or assess all criteria included in
the sPESI and Hestia tools. Inclusion of these data could
have only increased the percentage of patients classified
as higher-risk, and as a result, we likely underestimated
the percentage of patients at high-risk of early post-PE
mortality. However, nearly half of observation stay
patients in our analysis were identified as high-risk ac-
cording to the IMPACT equation, which was specifically
designed for identification of low-risk PE patients using
claims data and shown to have similar prognostic accuracy
for both in-hospital and 30-day mortality as PESI, sPESI
and Hestia [7–9]. Second, we did not have 30-day mor-
tality data available and therefore cannot comment on
whether these observation stay and higher-risk patients
had subsequent adverse outcomes after discharge. Fi-
nally, since the overall proportion of patients being
managed through observations stays in the US is limited,
it is possible that other unidentified factors (e.g., societal
or economic) are influencing the generalizability of these
findings.
Conclusion
Our analysis suggests patient selection for abbreviated
stays is not consistent with claims-based risk stratifica-
tion tools and accepted clinical criteria denoting higher-
risk for early mortality.
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Age (mean ± SD) 43.7 ± 12.3 70.1 ± 10.7 52.3 ± 15.8 63.4 ± 18.5
Male gender 385 (43.9) 340 (44.9) 503 (46.1) 222 (40.9)
High-risk criteria included in sPESI or Hestia criteria
Age >80 years 0 (0) 127 (16.8) 0 (0) 127 (23.4)
Heart failure 4 (0.5) 68 (9.0) 0 (0) 72 (13.3)
Chronic lung disease 91 (10.4) 226 (29.9) 0 (0) 317 (58.4)
Renal impairment 3 (0.3) 67 (8.9) 0 (0) 70 (12.9)
Severe liver disease 6 (0.7) 23 (3.0) 0 (0) 29 (5.3)
High risk for major
bleedinga
1 (0.1) 9 (1.2) 0 (0) 10 (1.8)
Cancer 0 (0) 46 (6.1) 0 (0) 46 (8.5)
Required thrombolysis or
embolectomy (days 0–2)
2 (0.2) 2 (0.3) 0 (0) 4 (0.7)
Estimated IMPACTb mortality
risk, % (mean ± SD)
1.0 ± 0.3 3.2 ± 2.5 1.3 ± 0.7 3.4 ± 2.9
Myocardial infarction 1 (0.1) 0 (0) 0 (0) 1 (0.2)
Stroke 0 (0) 2 (0.3) 0 (0) 2 (0.4)
Atrial Fibrillation 3 (0.3) 85 (11.2) 31 (2.8) 57 (10.5)
Cognitive impairment 0 (0) 57 (7.5) 14 (1.3) 43 (7.9)
Coagulopathy 1 (0.1) 35 (4.6) 18 (1.7) 18 (3.3)
Length of stay, days
(mean ± SD)









IMPACT In-hospital Mortality for PulmonAry embolism using Claims daTa, SD standard deviation, sPESI simplified pulmonary embolism severity index
aActive or recent history of major bleed
bThe multivariable IMPACT equation is: 1/(1 + exp(−x); where x = −5.833 + (0.026*age) + (0.402*myocardial infarction) + (0.368*chronic lung disease) + (0.464*stroke)
+ (0.638*prior major bleeding) + (0.298*atrial fibrillation) + (1.061*cognitive impairment) + (0.554*heart failure) + (0.364*renal failure) + (0.484*liver disease)
+ (0.523*coagulopathy) + (1.068*cancer)
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